All Stories

  1. Randomised trial of delivering co-located, personalised stop-smoking support within lung cancer screening: the YESS study
  2. State-of-the-Art Machine Learning Models for Detecting and Mitigating Disparities in Healthcare
  3. Towards Inclusive AI System Development for Disease Risk Prediction: Collecting, Prioritising and Incorporating User Stories from Heterogeneous Stakeholders
  4. Utilization of Lung Cancer Registries in Learning Health Systems for Health Care Improvement
  5. Effective management of incidental findings in lung cancer screening: the role of the screening review meeting
  6. Increasing Lung Screening uptake: Exploring people who smoke and their family members concerns and recommendations regarding screening invitations
  7. Explainable Boosting Machines for Lung Cancer Prediction and Explanation
  8. Decision Tree Models to Select High-Risk Patients for Lung Cancer Screening and Model Interpretability
  9. Achieving earlier diagnosis of symptomatic lung cancer
  10. Quality assurance in lung cancer screening
  11. Pulmonary fibrosis and lung cancer: an analysis of the Clinical Practice Research Datalink linked to the National Cancer Registration Dataset
  12. The importance of co-located, high intensity smoking cessation support within lung cancer screening: Findings from the Process Evaluation of the Yorkshire Enhanced Stop Smoking study
  13. Uptake and 4-week quit rates from an opt-out co-located smoking cessation service delivered alongside community-based low-dose computed tomography screening within the Yorkshire Lung Screening Trial
  14. Impact of the SARS-CoV-2 pandemic on lung cancer survival in England: an analysis of the rapid cancer registration dataset
  15. Measuring Harms of Lung Cancer Screening
  16. Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models
  17. Measuring spirometry in a lung cancer screening cohort highlights possible underdiagnosis and misdiagnosis of COPD
  18. The Impact of COVID-19 on Lung Cancer Incidence in England
  19. Developing a pan-European technical standard for a comprehensive high-quality lung cancer computed tomography screening programme: an ERS technical standard
  20. Defining the road map to a UK national lung cancer screening programme
  21. Recalibration of a Deep Learning Model for Low-Dose Computed Tomographic Images to Inform Lung Cancer Screening Intervals
  22. Lung cancer screening
  23. Lung nodules: sorting the wheat from the chaff
  24. Clinical trials in cancer screening, prevention and early diagnosis (SPED): A systematic mapping review
  25. Important parameters for cost-effective implementation of lung cancer screening
  26. Decision Tree Approaches to Select High Risk Patients for Lung Cancer Screening Based on the UK Primary Care Data
  27. Logistic Regression Approach to a Joint Classification and Feature Selection in Lung Cancer Screening Using CPRD Data
  28. Co-development of an evidence-based personalised smoking cessation intervention for use in a lung cancer screening context
  29. European Respiratory Society guideline on various aspects of quality in lung cancer care
  30. Impact of radiographer immediate reporting of X-rays of the chest from general practice on the lung cancer pathway (radioX): a randomised controlled trial
  31. An International Consensus on Actions to Improve Lung Cancer Survival: A Modified Delphi Method Among Clinical Experts in the International Cancer Benchmarking Partnership
  32. Decision Support Tools for Low-Dose CT Lung Cancer Screening
  33. Co-development of an evidence-based personalised smoking cessation intervention for use in a lung cancer screening context
  34. Participation in community-based lung cancer screening: the Yorkshire Lung Screening Trial
  35. Predicting the future risk of lung cancer: development and validation of QCancer2 (10-year risk) lung model and evaluating the model performance of nine prediction models
  36. Acceptability of a standalone written leaflet for the National Health Service for England Targeted Lung Health Check Programme: A concurrent, think‐aloud study
  37. The role of computer-assisted radiographer reporting in lung cancer screening programmes
  38. Attitudes towards the integration of smoking cessation into lung cancer screening in the United Kingdom: A qualitative study of individuals eligible to attend
  39. Implementing Lung Cancer Screening in Europe: Taking a Systems Approach
  40. Ninety-day mortality following lung cancer surgery: outcomes from the English national clinical outcomes audit
  41. Lung Cancer in the United Kingdom
  42. Management of Lung Cancer Screening Results Based on Individual Prediction of Current and Future Lung Cancer Risks
  43. The Future of Lung Cancer Screening: Current Challenges and Research Priorities
  44. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
  45. Analysis of the baseline performance of five UK lung cancer screening programmes
  46. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis
  47. Selection of eligible participants for screening for lung cancer using primary care data
  48. What is the Definition of Cure in Non-small Cell Lung Cancer?
  49. International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study
  50. Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial)
  51. Correction: Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom
  52. Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom
  53. Factors associated with survival in small cell lung cancer: an analysis of real-world national audit, chemotherapy and radiotherapy data
  54. Participation in lung cancer screening
  55. Importance of research design in biomarkers for lung cancer
  56. Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation
  57. Selecting Lung Cancer Patients from UK Primary Care Data: A Longitudinal Study of Feature Trends
  58. Reply to Wilson: Improving Lung Cancer Screening Uptake
  59. Pulmonary nodules
  60. New fissure-attached nodules in lung cancer screening: more practical implications from the NELSON study?
  61. An update on CT screening for lung cancer: the first major targeted cancer screening programme
  62. Yorkshire Enhanced Stop Smoking (YESS) study: a protocol for a randomised controlled trial to evaluate the effect of adding a personalised smoking cessation intervention to a lung cancer screening programme
  63. Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk
  64. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer
  65. Lung Screen Uptake Trial: results from a single lung cancer screening round
  66. Targeted screening for lung cancer is here but who do we target and how?
  67. SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection
  68. Prevalence, Symptom Burden, and Underdiagnosis of Chronic Obstructive Pulmonary Disease in a Lung Cancer Screening Cohort
  69. Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe
  70. Lung Screen Uptake Trial (LSUT): Randomized Controlled Clinical Trial Testing Targeted Invitation Materials
  71. Lung cancer: investigation and staging
  72. External validation of a convolutional neural network artificial intelligence tool to predict malignancy in pulmonary nodules
  73. A systematic review of survival following anti-cancer treatment for small cell lung cancer
  74. Post-treatment survival difference between lobectomy and stereotactic ablative radiotherapy in stage I non-small cell lung cancer in England
  75. Correction:Defining the information needs of lung cancer screening participants: a qualitative study
  76. Defining the information needs of lung cancer screening participants: a qualitative study
  77. Impact of choice of volumetry software and nodule management guidelines on recall rates in lung cancer screening
  78. Evaluation of cardiovascular risk in a lung cancer screening cohort
  79. Ex vivo Raman spectroscopy mapping of lung tissue: label-free molecular characterization of nontumorous and cancerous tissues
  80. Benefits and harms in the National Lung Screening Trial: expected outcomes with a modern management protocol
  81. Impact of a Lung Cancer Screening Information Film on Informed Decision-making: A Randomized Trial
  82. Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial
  83. Probability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial
  84. The potential of breath analysis to improve outcome for patients with lung cancer
  85. Status of Lung Cancer Data Collection in Europe
  86. Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries
  87. Lung cancer screening – gaining consensus on next steps – proceedings of a closed workshop in the UK
  88. Factors influencing treatment selection and 30-day mortality after chemotherapy for people with small-cell lung cancer: An analysis of national audit data
  89. ERS Statement on harmonised standards for lung cancer registration and lung cancer services in Europe
  90. EUPS—argues that lung cancer screening should be implemented in 18 months
  91. Lung cancer screening—low dose CT for lung cancer screening: recent trial results and next steps
  92. The continuum of screening and early detection, awareness and faster diagnosis of lung cancer
  93. Lung cancer in the UK: addressing geographical inequality and late diagnosis
  94. The Fleischner Society 2017 and British Thoracic Society 2015 guidelines for managing pulmonary nodules: keep calm and carry on
  95. British Thoracic Society quality standards for the investigation and management of pulmonary nodules
  96. Patient selection for future lung cancer computed tomography screening programmes: lessons learnt post National Lung Cancer Screening Trial
  97. Recent advances in the management of lung cancer
  98. Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients
  99. Low-dose CT for lung cancer screening – Authors' reply
  100. Low dose CT screening for lung cancer
  101. European position statement on lung cancer screening
  102. Impact of radiographer immediate reporting of chest X-rays from general practice on the lung cancer pathway (radioX): study protocol for a randomised control trial
  103. Treatment recommendations for stage I non-small cell lung cancer: does patient preference matter?
  104. Use of Volumetry for Lung Nodule Management: Theory and Practice
  105. Physician Assessment of Pretest Probability of Malignancy and Adherence to Guidelines for Pulmonary Nodule Evaluation
  106. Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial
  107. The impact of trained radiographers as concurrent readers on performance and reading time of experienced radiologists in the UK Lung Cancer Screening (UKLS) trial
  108. Lung cancer in symptomatic patients presenting in primary care: a systematic review of risk prediction tools
  109. Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study
  110. Socioeconomic position and delays in lung cancer diagnosis: should we target the more deprived?
  111. What is the Optimum Screening Strategy for the Early Detection of Lung Cancer
  112. Optimum low dose CT screening interval for lung cancer: the answer from NELSON?
  113. Comparing the performance of trained radiographers against experienced radiologists in the UK lung cancer screening (UKLS) trial
  114. Erratum to: The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with periphe...
  115. Implementation planning for lung cancer screening: five major challenges
  116. How should performance in EBUS mediastinal staging in lung cancer be measured?
  117. Place of Death in Patients with Lung Cancer: A Retrospective Cohort Study from 2004-2013
  118. Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial
  119. Defining a standard set of patient-centred outcomes for lung cancer
  120. Lung cancer risk in new pulmonary nodules: implications for CT screening and nodule management
  121. Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data
  122. Predicting death from surgery for lung cancer: A comparison of two scoring systems in two European countries
  123. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer
  124. Management of pulmonary nodules according to the 2015 British Thoracic Society guidelines. Key messages for clinical practice
  125. The Lung Screen Uptake Trial (LSUT): protocol for a randomised controlled demonstration lung cancer screening pilot testing a targeted invitation strategy for high risk and ‘hard-to-reach’ patients
  126. Lung cancer: investigation and staging
  127. Return of the pulmonary nodule: the radiologist's key role in implementing the 2015 BTS guidelines on the investigation and management of pulmonary nodules
  128. Pulmonary nodules and CT screening: the past, present and future
  129. The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I ...
  130. How should pulmonary nodules be optimally investigated and managed?
  131. CT screening for lung cancer: Is the evidence strong enough?
  132. Integrated Raman microscopy and auto-fluorescence imaging for fast tumour diagnosis during cancer surgery
  133. Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention
  134. Pulmonary nodules again? The 2015 British Thoracic Society guidelines on the investigation and management of pulmonary nodules
  135. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening
  136. Development of Guidelines for the Management of Pulmonary Nodules Toward Better Implementation
  137. Correction
  138. Patients’ attitudes to risk in lung cancer surgery: A qualitative study
  139. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators
  140. Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial
  141. Prediction of risk of lung cancer in populations and in pulmonary nodules: Significant progress to drive changes in paradigms
  142. Reliable EGFR mutation testing in ultrasound-guided supraclavicular lymph node fine-needle aspirates: a cohort study with diagnostic performance analysis
  143. The British Thoracic Society guidelines on the investigation and management of pulmonary nodules
  144. British Thoracic Society guidelines for the investigation and management of pulmonary nodules: accredited by NICE
  145. Screening for lung cancer
  146. Screening
  147. Plasma lipid biomarker signatures in squamous carcinoma and adenocarcinoma lung cancer patients
  148. FDG-PET/CT Imaging for Mediastinal Staging in Patients With Potentially Resectable Non–Small Cell Lung Cancer
  149. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial
  150. Non-small cell lung cancer in young adults: presentation and survival in the English National Lung Cancer Audit
  151. Author's response: What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK?
  152. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer
  153. Next steps and barriers to implementing lung cancer screening with low-dose CT
  154. Brain metastases following radical surgical treatment of non-small cell lung cancer: Is preoperative brain imaging important?
  155. What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK?
  156. The impact of the ‘hub and spoke’ model of care for lung cancer and equitable access to surgery
  157. Appetite stimulants for people with cystic fibrosis
  158. The European initiative for quality management in lung cancer care
  159. Lung cancer screening with low dose computed tomography
  160. The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening
  161. Small-Cell Lung Cancer in England: Trends in Survival and Chemotherapy Using the National Lung Cancer Audit
  162. Multidisciplinary team management in thoracic oncology: more than just a concept?
  163. The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) Response to the USPSTF Recommendations
  164. Effective lung cancer screening is possible
  165. Treatment decisions and survival for people with small-cell lung cancer
  166. CT screening for lung cancer: countdown to implementation
  167. Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009
  168. Lung cancer survival in England: trends in non-small-cell lung cancer survival over the duration of the National Lung Cancer Audit
  169. European randomized lung cancer screening trials: Post NLST
  170. Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit
  171. Chronic Obstructive Pulmonary Disease and Risk of Lung Cancer: The Importance of Smoking and Timing of Diagnosis
  172. The pathological confirmation rate of lung cancer in England using the NLCA database
  173. Using socio-demographic and early clinical features in general practice to identify people with lung cancer earlier
  174. Chronic Obstructive Pulmonary Disease and Risk of Lung Cancer: The Importance of Smoking and Timing of Diagnosis
  175. The Association Between Smoking Quantity and Lung Cancer in Men and Women
  176. Authors' response
  177. Measurement Methods and Algorithms for the Management of Solid Nodules
  178. A proposed new imaging pathway for patients with suspected lung cancer
  179. The (US) National Lung Cancer Screening Trial: intensifying the debate about the introduction of screening for lung cancer
  180. What is the Most Effective Follow-up Model for Lung Cancer Patients? A Systematic Review
  181. Lung cancer: investigation and staging
  182. Authors' response
  183. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 Report
  184. Supportive Care in Respiratory Disease
  185. Authors' response
  186. How do patient and hospital features influence outcomes in small-cell lung cancer in England?
  187. Inequalities in outcomes for non-small cell lung cancer: the influence of clinical characteristics and features of the local lung cancer service
  188. CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report
  189. Diagnosis and treatment of lung cancer: summary of updated NICE guidance
  190. Lung cancer in England: Information from the National Lung Cancer Audit (LUCADA)
  191. Imaging in lung cancer: recent advances in PET-CT and screening
  192. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer
  193. Authors' response
  194. Guidelines on the radical management of patients with lung cancer
  195. Diagnosing lung cancer earlier in the UK
  196. Technical validation of an autoantibody test for lung cancer
  197. Cardiopulmonary exercise testing for the selection of patients undergoing surgery for lung cancer: friend or foe?
  198. Cytological assessment of conventional transbronchial fine needle aspiration of lymph nodes
  199. Lung cancer: investigation and staging
  200. Appetite stimulants in cystic fibrosis: a systematic review
  201. BTS statement on malignant mesothelioma in the UK, 2007
  202. NICE guidance for screening for malnutrition: implications for lung cancer services
  203. Lung cancer outcomes at a UK cancer unit between 1998–2001
  204. Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway
  205. Evaluation of the solitary pulmonary nodule: clinical management, role of CT and nuclear medicine
  206. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy
  207. Interpretation of occupational peak flow records: level of agreement between expert clinicians and Oasys-2
  208. Management of solitary pulmonary nodules: how do thoracic computed tomography and guided fine needle biopsy influence clinical decisions?
  209. Questionnaire survey of male infertility in cystic fibrosis
  210. Development of an expert system for the interpretation of serial peak expiratory flow measurements in the diagnosis of occupational asthma. Midlands Thoracic Society Research Group.
  211. How Do General Practitioners Respond to Reports of Abnormal Chest X-rays?
  212. Comparison of two new methods for the measurement of lung volumes with two standard methods
  213. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis
  214. Comparative clinical and physiological features of Maori, Pacific Islanders and Europeans with sleep related breathing disorders
  215. Effect of two types of mandibular advancement splints on snoring and obstructive sleep apnoea
  216. Pragmatics: Principals of Design and Evaluation of an Information System for a Department of Respiratory Medicine
  217. Non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease
  218. Silicosis presenting as bilateral hilar lymphadenopathy.
  219. SHORT COMMUNICATION: Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers
  220. Effect of diuretics on allergen-induced contractions of passively sensitized human bronchi in vitro.
  221. Nocturnal oxygen desaturation and exercise-induced desaturation in subjects with chronic obstructive pulmonary disease
  222. Concentrations of ceftibuten in plasma and the respiratory tract following a single 400 mg oral dose
  223. Scoring system developed for drug related morbidity
  224. Comparison of the effects of salbutamol and adrenaline on airway smooth muscle contractility in vitro and on bronchial reactivity in vivo.
  225. The concentration of sparfloxacin in lung tissues after single and multiple oral doses
  226. The levels of clarithromycin and its 14-hydroxy metabolite in the lung
  227. Cross refractoriness between sodium metabisulphite and exercise induced asthma.
  228. Effect of addition of exercise to chest physiotherapy on sputum expectoration and lung function in adults with cystic fibrosis
  229. The Effect of Sodium Transport and Calcium Channel Inhibitors on Phorbol Ester-induced Contraction of Bovine Airway Smooth Muscle
  230. Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration
  231. Laparoscopic cholecystectomy in patients with cystic fibrosis
  232. Quantitative morphology and water distribution of bronchial biopsy samples.
  233. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance.
  234. Pulmonary disposition of antimicrobial agents: methodological considerations.
  235. Bronchoalveolar distribution of cefaroxime axetil and in-vitro efficacy of observed concentrations against respiratory pathogens
  236. Concentrations of cefpodoxime in serum and bronchial mucosal biopsies
  237. The site concentrations of antimicrobial agents in the lung
  238. Microlavage: a technique for determining the volume of epithelial lining fluid.
  239. Comparative pharmacokinetic disposition of fluoroquinolones in the lung
  240. In-vitro activity and β-lactamase stability of SR 44337, a new long acting cephalosporin
  241. In-vitro susceptibility of Chlamydia pneumoniae (TWAR) to seven antibiotics
  242. The penetration of cefpirome into the potential sites of pulmonary infection
  243. Concentrations of oral lomefloxacin in serum and bronchial mucosa.
  244. Concentrations of temafloxacin in serum and bronchial mucosa
  245. Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens.
  246. Cefepime concentrations in bronchial mucosa and serum following a single 2 gram intravenous dose